Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LLX-424 in kidney stone patients
NCT06932146Phase 2Completed
- Sponsor
- Lilac Therapeutics
- Start
- Mar 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nephrolithiasis comparing LLX-424 with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events at 9 weeks, Percentage of subjects with study drug-related severe laboratory-based adverse events at 9 weeks and 1 more. Started Mar 2025; status: completed.
02
Drugs
LLX-424
03
Conditions
nephrolithiasis
Beyond the preview
Go deeper on NCT06932146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932146.